Pemphigus Vulgaris Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Pemphigus Vulgaris remains an active clinical development field. Clinical competition is shifting from broad immunosuppression toward pathway-selective control, durable remission and treatment strategies that reduce steroid exposure without trading away safety. The PatSnap evidence set used here contains 62 matched trial records and 28 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07681388 | Anti-BCMA and CD19 CART(Anhui Provincial Hospital) | Not Applicable; Recruiting | Sponsor not listed | China | Incidence and Severity of Treatment-Emergent Adverse Events (From initiation of lymphodepleting chemotherapy through Day 90 after CAR-T…); Change From Baseline in PDAI Score at Week 12 (Baseline and Week 12) | 2026-12-30 |
| NCT07641725 | Clobetasol Propionate | Not Applicable; Recruiting | Damascus University | Syria | Pemphigus Disease Area Index (PDAI) (Patients will be followed up on Days 7, 14, 21, 28, 42, 60, and 90); Oral Disease Severity Score (ODSS) (Patients will be followed up on Days 7, 14, 21, 28, 42, 60, and 90) | 2026-09-01 |
| ChiCTR2600123534 | Intervention not normalized | Not Applicable; Not yet recruiting | Nanfang Hospital | China | Complete remission (At 24 weeks) | 2027-04-30 |
| ChiCTR2600121847 | Intervention not normalized | Not Applicable; Recruiting | Peking Union Medical College Hospital; Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences | China | Hospital Anxiety and Depression Scale (After admission, before discharge) | 2027-12-01 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- CAR T therapy without preconditioning in pemphigus vulgaris: Early clinical and translational data with resecabtagene autoleucel, an autologous 4-1BB CD19- CAR T (Phase 1/2): the indexed record reports CRS(grade 1) = 1.0 pts.
- An Open-Label, Multicenter, Follow-up Trial of ARGX-113-1904 to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Pemphigus (Phase 3): the indexed record reports -; TEAE = 113.0 number of events x 100/PYFU; TEAE = 116.4 number of events x 100/PYFU.
- A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Pemphigus (Vulgaris or Foliaceus) (Phase 3): the indexed record reports Number of Pemphigus Vulgaris (PV) Participants Who Achieve Complete Clinical Remission (CR) on Minimal Prednisone Therapy = 20 Participants; -; Number of Pemphigus Vulgaris (PV) Participants Who Achieve Complete Clinical Remission (CR) on Minimal Prednisone Therapy = 44 Participants.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Anti-BCMA and CD19 CART(Anhui Provincial Hospital) (Clinical; BCMA x CD19), Clobetasol Propionate (Approved; GR). Company & Deal Intelligence records identify sponsor context for Damascus University, Nanfang Hospital, Peking Union Medical College Hospital, Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Standard definitions for steroid-free remission and durable disease control.
- Head-to-head trials against current targeted standards, not placebo alone.
- Biomarker strategies that distinguish mechanistic responders before prolonged treatment.
- Long-term infection, malignancy and immune-reconstitution follow-up.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Pemphigus Vulgaris has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
